Valuation dashboard for Creative Medical Technology Holdings, Inc. (CELZ) with P/E N/A, P/B 0.35, EV/EBITDA 0.96 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology.
Analysis Summary
Creative Medical Technology Holdings, Inc. reported revenue of $6000 in the most recent fiscal year, growing at a 5-year CAGR of -48.4%.
Trailing-twelve-month margins: gross margin -17.3%, operating margin -2080.0%, net margin -2013.6%.
At the current price of $0.82, CELZ has negative trailing earnings (P/E not meaningful) and an ROE of -86.70%. Market capitalisation stands at $2M.
Balance sheet quality for CELZ: current ratio of 26.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.35 |
| EV / EBITDA | 0.96 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $2.94 |
| vs Current Price | +257.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CELZ | Creative Medical Technology Holdings, Inc. | $2M | 0.35 | -86.7% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.82 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -86.70% |
| Return on Invested Capital | -71.90% |
| Return on Assets | -64.42% |
| Gross Margin | -1732.37% |
| Operating Margin | -208004.40% |
| Net Margin | -201355.37% |
Related companies: ACXP · ADIL · ADXN · ALZN · APRE · BCDA · CDIO
Explore sector: Healthcare · Biotechnology
More sections of CELZ: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks